Positive Phase 2 Results Claimed for Masitinib in Alzheimer’s
Topline results suggested that the anti-inflammatory treatment stabilized cognition and function over six months. The trial did not include biomarkers.
ALL NEWS
46 RESULTS
Sort By:
- Most Recent
- Most Commented
Current Filters
- Date Range : Oct 2020 to Jan 2021 x